Breaking News
October 23, 2018 - Polyganics begins first-in-human clinical trial of LIQOSEAL for reducing CSF leakage
October 23, 2018 - Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
October 23, 2018 - Cardiovascular admissions more common among most deprived
October 23, 2018 - Targeted drug and hormone therapy combination extends breast cancer survival
October 23, 2018 - Map of human liver cells reveals molecular make-up of individual cells
October 23, 2018 - Drugs approved for breast cancer treatment are effective and well tolerated in men
October 23, 2018 - EKF introduces new hand-held lactate analyzer for rapid sports performance monitoring
October 23, 2018 - Researchers identify common genetic connection in lung conditions
October 23, 2018 - Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC
October 23, 2018 - Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer
October 23, 2018 - New discovery may lead to better treatment options for pancreatic cancer patients
October 23, 2018 - FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
October 23, 2018 - Researchers identify immune culprits linked to inflammation and bone loss in gum disease
October 23, 2018 - Despite lower risk factors, black men have higher rates of recidivism
October 23, 2018 - Study finds why pregnant women in mainland China, Hong Kong and Taiwan prefer cesarean delivery
October 23, 2018 - AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis
October 23, 2018 - NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors
October 23, 2018 - Scientists use electron microscope to study chemical transformation in catalytic cross-coupling reaction
October 23, 2018 - Research offers new hope to men who received childhood cancer treatment
October 23, 2018 - New medical navigation system receives international innovation award
October 23, 2018 - Adverse Childhood Experiences Tied to Burnout in BSN Students
October 23, 2018 - High levels of oral disease among elite athletes affecting performance
October 23, 2018 - Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
October 23, 2018 - LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
October 23, 2018 - Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
October 23, 2018 - Organic food may protect against cancers finds study
October 23, 2018 - Interweaving anxiety disorder associated with stuttering remains unrecognized
October 23, 2018 - Cannabis oil shown to significantly improve Crohn’s disease symptoms
October 23, 2018 - Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
October 23, 2018 - Common antibodies associated with myocardial infarction
October 23, 2018 - Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
October 23, 2018 - Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
October 23, 2018 - Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
October 23, 2018 - Can virtual reality help people become more compassionate?
October 23, 2018 - Screen time eclipsed outdoor time for most students, shows study
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
October 23, 2018 - Cancer stem cells use ‘normal’ genes in abnormal ways
October 23, 2018 - Bad Blood: A conversation with investigative reporter John Carreyrou | News Center
October 23, 2018 - As U.S. fertility rates collapse, finger-pointing and blame follow
October 23, 2018 - Researchers develop promising targeted strategy to treat chemo-resistant blood cancer
October 23, 2018 - Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus
October 23, 2018 - Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
October 23, 2018 - 11th World Stroke Congress examines high stroke impact in low- and middle-income countries
October 22, 2018 - Breast cancer survival could be extended with two new drug combinations
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Innovative strategy opens up new avenue of treatment for anthrax infections
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Drug cocktail that increases lifespan discovered
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Study shows potential positive impact of group prenatal care on birth outcomes
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
CDx Diagnostics announces WATS3D data demonstrating crypt dysplasia as risk factor for esophageal cancer

CDx Diagnostics announces WATS3D data demonstrating crypt dysplasia as risk factor for esophageal cancer

image_pdfDownload PDFimage_print

CDx Diagnostics, an innovator in computer-synthesized, three dimensional tissue analysis for the early detection and surveillance of Barrett’s esophagus, today announced new data for WATS3D, or Wide Area Transepithelial Sampling with 3D Tissue Analysis, demonstrating the clinical significance of crypt dysplasia as an important risk factor for progression to high-grade esophageal dysplasia or esophageal cancer.

Dr. Nicholas Shaheen, Chief, Division of Gastroenterology & Hepatology University of North Carolina at Chapel Hill is presenting the data today in a Presidential Plenary session at ACG 2018, the annual meeting of the American College of Gastroenterology, taking place October 5 -10 in Philadelphia.

WATS Computer Synthesized En Face View of Crypt Dysplasia. Credit: CDx Diagnostics

Detecting still harmless, but pre-cancerous dysplasia can prevent the development of esophageal adenocarcinoma, the most rapidly growing cancer in the U.S., and one of the most fatal.

Accurately identifying which chronic heartburn patients who develop Barrett’s esophagus have also progressed to dysplasia can have an important impact on patient care.

The clinical significance of dysplasia involving crypt cells has not been well understood due to limitations in detecting crypt dysplasia by conventional biopsies. The data reported today suggest that samples obtained and analyzed with WATS3D allow detection of this condition.

Most importantly, the data also suggest that crypt dysplasia is something we should wish to detect, because it has a higher risk of progression to high-grade dysplasia or esophageal cancer compared to non-dysplastic Barrett’s. Together, the data suggest that WATS3D provides information that forceps biopsy cannot.”

Dr. Nicholas Shaheen

Barrett’s esophagus (BE) occurs when the normal epithelial lining of the esophagus is replaced by goblet cells that are typically found in the lower gastrointestinal tract.

Patients with BE have an increased risk of developing esophageal adenocarcinoma (EAC), a cancer that attacks 17,000 people in the United States each year – of which 16,000  will die from.

Given this risk, it is recommended that patients with BE undergo periodic surveillance endoscopy to monitor for pre-cancerous changes to the esophageal lining.

While non-dysplastic BE (NDBE), low- or high-grade dysplasia (LGD or HGD, respectively) can be diagnosed using standard biopsy criteria, morphologic changes that fell between NDBE and LGD were traditionally classified as indefinite for dysplasia and often grouped with NDBE due to the inability to distinguish dysplasia involving crypt cells (which are located below the epithelial cells) from esophagitis resulting from uncontrolled reflux.

Due in part to the inability to accurately diagnose crypt dysplasia (CD), its clinical significance has not been well understood.

The study results presented today are the first to show that WATS3D enables accurate diagnosis of CD as a distinct histology; they also show that CD is a risk factor for HGD and EAC and that progression rates from NDBE and LGD to HGD/EAC detected with WATS3D are similar to those obtained using traditional forceps biopsies.

What has been under appreciated by clinicians is how incredibly effective the WATS3D computer-assisted analysis and neural network program is at helping pathologists detect dysplasia and, most notably, its earliest form, termed crypt dysplasia.

The WATS 3D technology allows pathologists to ‘put into focus’ atypical lesions that would otherwise be considered indefinite.

The results of this study prove, for the first time, that early dysplastic lesions are clearly important to detect because of their now established increased risk of neoplastic progression. Thus, computer-assisted pathologic detection of these lesions will undoubtedly improve patient care.”

Dr. Robert D. Odze, Harvard Medical School

The study reported at ACG 2018 followed 4,512 patients who had two WATS3D assessments six months apart. Patient-years (pt-yrs) were calculated by multiplying the mean period of follow-up by the number of patients with each type of histology.

Of 4,512 patients, 4,049 with NDBE at baseline were followed for an average of 1.4 years between WATS3D assessments (5,736 pt-yrs) and 380 with NDBE at baseline were followed for an average of 1.25 years between assessments (475 pt-yrs). An additional 83 patients had LGD at baseline WATS3D and were followed for a mean of 1.25 years (103.7 pt-yrs). Key findings from the study include:

  • 19 of the NDBE patients followed for 1.4 years experienced progression to HGD/EAC, for a rate of 0.33%/pt-yr.
  • 10 of the NDBE patients followed for 1.25 years experienced progression to HGD/EAC, for a rate of 2.1%/pt-yr.
  • 8 of the LGD patients experienced progression to HGD/EAC, for a rate of 7.7%/pt-yr.
  • The overall rate of progression from WATS3D-determined CD to LGD/HGD/EAC was 9.9%/pt-yr, which is comparable to the rate of progression from biopsy-confirmed LGD.
  • Results show that a finding of NDBE or LGD on WATS3D predicts progression to HGD/EAC at rates that are comparable to or higher than the reported risk of progression when these histologies are determined by biopsy.
  • For patients with BE, CD or LGD at baseline, the trend for progression to HGD/EAC was statistically significant.

“These results highlight the clinical benefits that WATS3D provides with respect to accurate surveillance of esophageal changes in patients with BE,” said Mark Rutenberg, Founder and CEO of CDx Diagnostics.

“We believe these data highlight how WATS3D provides physicians and patients with accurate and critical information that can inform the management of BE and help preempt esophageal cancer. The fact that WATS3D accurately differentiates CD from reflux esophagitis, which is not feasible with forceps biopsy analyses, adds to its already compelling value proposition and advances our ability to achieve our vision of preventing unnecessary cancer deaths.”

Source:

https://www.cdxdiagnostics.com/

Tagged with:

About author

Related Articles